swisspartners’s TuHURA Biosciences HURA Stock Holding History

swisspartners’s Portfolio HURA Stock Details HURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-157	Closed	-$30K	–	84
2022 Q3	$30K	Hold	157	–	–	0.03%	79
2022 Q2	$79K	Hold	157	–	–	0.08%	76
2022 Q1	$109K	Hold	157	–	–	0.09%	80
2021 Q4	$142K	Hold	157	–	–	0.1%	80
2021 Q3	$237K	Hold	157	–	–	0.18%	72
2021 Q2	$624K	Hold	157	–	–	0.44%	54
2021 Q1	$479K	Buy	+157	New	+$533K	0.39%	56

Other funds holding HURA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

swisspartners's HURA Position: Q4 2022 in Review

swisspartners sold out of TuHURA Biosciences (HURA) in Q4 2022, closing a stake of 157 shares — an estimated $30K sold.

swisspartners first reported a position in HURA in Q1 2021 and held it in 7 quarters. The position peaked at $624K in Q2 2021. 10 funds tracked by Wall St. Rank hold HURA as of Q4 2022.

swisspartners reported no remaining TuHURA Biosciences position as of Q4 2022 after selling out during the quarter.
swisspartners sold 157 TuHURA Biosciences shares in Q4 2022, an estimated $30K.
swisspartners first reported a position in TuHURA Biosciences in Q1 2021 and held it in 7 quarters.
swisspartners's TuHURA Biosciences position peaked at $624K in Q2 2021.
10 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q4 2022.

Based on swisspartners's 13F filing for Q4 2022, filed 14 Feb 2023.